Bd E-Z Scrub

Description

BD E-Z Scrub is a chlorhexidine gluconate 2% solution antiseptic, indicated for use in various medical settings. The product is packaged in a 32 fl oz (946 mL) container and is identified by NDC 17271-506-02. It is associated with U.S. Patent 6,427,875, along with foreign patents and patents pending. The active ingredient, chlorhexidine gluconate, serves as the primary antiseptic component in this formulation.

Uses and Indications

This drug is indicated for use as a surgical hand scrub, significantly reducing the number of microorganisms on the hands and forearms prior to surgical procedures or patient care. Additionally, it is indicated for healthcare personnel handwashing, aiding in the reduction of bacteria that may potentially cause disease.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Surgical hand scrubbing requires the following procedure: Healthcare professionals should begin by wetting their hands and forearms with water. They should then apply 5 ml of the solution, using a wet brush to scrub for 3 minutes, ensuring to perform 4 full strokes while paying particular attention to the nails, cuticles, and interdigital spaces. A separate nail cleaner may be utilized if necessary. After scrubbing, hands must be rinsed thoroughly. Following this initial scrub, an additional wash is required, where 5 ml of the solution should again be applied for another 3 minutes, with 4 full strokes, before rinsing under running water. It is essential to dry hands thoroughly after this process.

For healthcare personnel handwashing, the procedure begins with wetting the hands with water. The individual should dispense 5 ml of the solution into cupped hands and wash vigorously for 15 seconds. After washing, hands must be rinsed under running water and dried thoroughly.

Contraindications

Use of this product is contraindicated in individuals with a known allergy to chlorhexidine gluconate or any other component of the formulation.

Additionally, the product should not be used routinely in patients with wounds that extend beyond the superficial layers of the skin, as this may pose a risk of complications.

Care should be taken to avoid contact with the eyes, ears, and mouth, as exposure may result in serious and permanent injury, including potential deafness if introduced into the middle ear through perforated eardrums. In the event of contact with these areas, it is imperative to rinse thoroughly with water.

Discontinue use and consult a healthcare professional if signs of irritation, sensitization, or allergic reaction occur, as these may indicate a serious condition.

Warnings and Precautions

For external use only. This product carries a significant risk of causing severe allergic reactions. Symptoms indicative of such reactions may include wheezing or difficulty breathing, shock, facial swelling, hives, and rash. In the event of an allergic reaction, it is imperative to discontinue use immediately and seek medical assistance.

General precautions must be observed to ensure safe application. The product should be kept away from the eyes, ears, and mouth, as contact with these areas may result in serious and permanent eye injury or potential deafness if introduced into the middle ear through perforated eardrums. Should the solution inadvertently contact these sensitive areas, it is essential to rinse thoroughly with water without delay. Additionally, this product should not be used routinely on wounds that extend beyond the superficial layers of the skin.

In cases of accidental ingestion, immediate medical help should be sought, or a Poison Control Center should be contacted without delay.

Healthcare professionals should advise patients to discontinue use and consult a physician if any signs of irritation, sensitization, or allergic reaction occur, as these may indicate a serious underlying condition.

Side Effects

Patients may experience a range of adverse reactions associated with the use of this product. Notably, there is a significant allergy alert, as the product has the potential to cause severe allergic reactions. Symptoms of such reactions may include wheezing or difficulty breathing, shock, facial swelling, hives, and rash. In the event of an allergic reaction, patients are advised to discontinue use immediately and seek medical assistance.

Additionally, the product should not be used by individuals who are allergic to chlorhexidine gluconate or any other ingredient contained in the formulation.

Patients should also be vigilant for signs of irritation, sensitization, or any allergic reactions during use. The occurrence of these symptoms may indicate a serious condition, and it is recommended that patients stop use and consult a healthcare professional if they arise.

Drug Interactions

There are currently no specific drug interactions identified for the medication. Additionally, no interactions with laboratory tests have been reported. Therefore, no dosage adjustments or monitoring recommendations are necessary at this time. It is advisable for healthcare professionals to remain vigilant and consult updated resources as new data may emerge.

Packaging & NDC

Below are the non-prescription pack sizes of Bd E-Z Scrub (chlorhexidine gluconate). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients, particularly premature infants and those under 2 months of age, should be treated with caution. The use of these products in this population may lead to irritation or chemical burns. It is essential for healthcare professionals to monitor these patients closely to mitigate potential risks associated with their use.

Geriatric Use

There is no specific information regarding the use of BD E-Z SCRUB (chlorhexidine gluconate solution) in geriatric patients. The prescribing information does not provide details on dosage adjustments, safety concerns, or special precautions that may be necessary for elderly patients.

Healthcare providers should exercise clinical judgment when considering the use of this product in geriatric populations, as individual patient factors may influence treatment decisions. Monitoring for any potential adverse effects is advisable, given the lack of targeted data for this demographic.

Pregnancy

There are no specific statements regarding the use of BD E-Z SCRUB (chlorhexidine gluconate solution) during pregnancy, including safety concerns, dosage modifications, or special precautions. As such, healthcare professionals should exercise caution when considering the use of this product in pregnant patients. The absence of data does not preclude the potential for unknown risks; therefore, the benefits and risks should be carefully weighed in the context of individual patient circumstances. Women of childbearing potential should be informed of the lack of specific pregnancy-related information and advised to consult their healthcare provider for personalized guidance.

Lactation

Lactating mothers should use this product with caution, particularly in the case of premature infants or those under 2 months of age. There is a risk that the product may cause irritation or chemical burns in breastfed infants. Therefore, careful consideration and monitoring are advised when administering this product to lactating mothers who are nursing infants in these vulnerable age groups.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the prescribing information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution when administering the medication. It is essential to monitor patients closely for any signs of adverse effects or symptoms that may arise from excessive dosing.

In the event of suspected overdosage, immediate medical attention should be sought. Healthcare providers should implement supportive measures as necessary, which may include symptomatic treatment and monitoring of vital signs.

Due to the lack of detailed overdosage information, it is recommended that healthcare professionals refer to established clinical guidelines and protocols for managing overdose situations relevant to the specific medication in question. Additionally, contacting a poison control center may provide further guidance on appropriate management strategies.

Continued vigilance and patient assessment are crucial in mitigating potential risks associated with overdosage.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the provided data.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. It is important to emphasize that if the medication is swallowed, patients should seek medical help or contact a Poison Control Center immediately. This guidance is crucial for ensuring the safety and well-being of patients and their families.

Storage and Handling

This product is supplied in various configurations, with specific NDC numbers available for identification. It is essential to store the product under controlled conditions to maintain its integrity and efficacy.

The recommended storage temperature range is between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). The product should be kept in its original container, ensuring that it is tightly closed to prevent contamination and degradation.

Special handling precautions should be observed due to the presence of coconut oil diethanolamine condensate (cocamide diethanolamine), which is recognized by the State of California as a potential carcinogen. For further information regarding safety and handling, please refer to www.P65Warnings.ca.gov.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Bd E-Z Scrub, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)